[go: up one dir, main page]

DK2145627T3 - Anvendelse af uridin i kombination med cholin til behandling af en humør-lidelse eller en følelsesmæssig lidelse. - Google Patents

Anvendelse af uridin i kombination med cholin til behandling af en humør-lidelse eller en følelsesmæssig lidelse.

Info

Publication number
DK2145627T3
DK2145627T3 DK09173495.4T DK09173495T DK2145627T3 DK 2145627 T3 DK2145627 T3 DK 2145627T3 DK 09173495 T DK09173495 T DK 09173495T DK 2145627 T3 DK2145627 T3 DK 2145627T3
Authority
DK
Denmark
Prior art keywords
choline
disorder
uridine
treatment
combination
Prior art date
Application number
DK09173495.4T
Other languages
English (en)
Inventor
Carol Watkins
Richard J Wurtman
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of DK2145627T3 publication Critical patent/DK2145627T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK09173495.4T 1998-07-31 1999-07-30 Anvendelse af uridin i kombination med cholin til behandling af en humør-lidelse eller en følelsesmæssig lidelse. DK2145627T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9500298P 1998-07-31 1998-07-31
EP07116909A EP1870103B1 (en) 1998-07-31 1999-07-30 Use of uridine in combination with choline for the treatment of memory disorders

Publications (1)

Publication Number Publication Date
DK2145627T3 true DK2145627T3 (da) 2014-07-21

Family

ID=22248474

Family Applications (5)

Application Number Title Priority Date Filing Date
DK07116909T DK1870103T3 (da) 1998-07-31 1999-07-30 Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse
DK99937631T DK1140104T3 (da) 1998-07-31 1999-07-30 Behandling af Alzheimer's sygdom ved forögelse af cytidinniveauer in vivo
DK09173495.4T DK2145627T3 (da) 1998-07-31 1999-07-30 Anvendelse af uridin i kombination med cholin til behandling af en humør-lidelse eller en følelsesmæssig lidelse.
DK10075660.0T DK2322187T3 (da) 1998-07-31 1999-07-30 Anvendelse af uridin i kombination med cholin til behandling af hukommelses-lidelser
DK10075661.8T DK2329829T3 (da) 1998-07-31 1999-07-30 Anveldelse af uridin i kombination med cholin til behandling af neurologiske lidelser

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK07116909T DK1870103T3 (da) 1998-07-31 1999-07-30 Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse
DK99937631T DK1140104T3 (da) 1998-07-31 1999-07-30 Behandling af Alzheimer's sygdom ved forögelse af cytidinniveauer in vivo

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK10075660.0T DK2322187T3 (da) 1998-07-31 1999-07-30 Anvendelse af uridin i kombination med cholin til behandling af hukommelses-lidelser
DK10075661.8T DK2329829T3 (da) 1998-07-31 1999-07-30 Anveldelse af uridin i kombination med cholin til behandling af neurologiske lidelser

Country Status (11)

Country Link
US (1) US6989376B2 (da)
EP (5) EP2329829B1 (da)
JP (1) JP2003517437A (da)
AT (2) ATE446097T1 (da)
CA (1) CA2339008C (da)
CY (1) CY1110570T1 (da)
DE (2) DE69941586D1 (da)
DK (5) DK1870103T3 (da)
ES (5) ES2477568T3 (da)
PT (5) PT2322187E (da)
WO (1) WO2000006174A1 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US20060069061A1 (en) * 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
AU2001247474A1 (en) * 2000-03-16 2001-09-24 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
MXPA05000451A (es) * 2002-07-11 2005-03-23 Yamasa Corp Composicion medicinal para neuropatia inducida por farmaco.
US7053064B2 (en) * 2002-11-08 2006-05-30 The Mclean Hospital Corporation Compounds for the treatment of tobacco dependence and withdrawal
CN100563660C (zh) * 2002-12-20 2009-12-02 麦克莱恩医院 用于正常化睡眠/觉醒周期的化合物
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005112635A2 (en) * 2004-05-13 2005-12-01 Massachusetts Institute Of Technology Uridine effects on dopamine release
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
AU2011253660B2 (en) * 2004-09-15 2013-12-19 Massachusetts Institute Of Technology Compositions containing uridine, and methods utilizing same
CN102600199A (zh) * 2004-09-15 2012-07-25 麻省理工学院 含有尿苷的组合物及使用其的方法
AU2012203650B2 (en) * 2005-05-23 2014-09-18 Massachusetts Institute Of Technology Compositions containing PUFA and methods of use thereof
CA2645647C (en) * 2005-05-23 2016-07-12 Massachusetts Institute Of Technology Compositions containing pufa and/or uridine and methods of use thereof
AU2006293026B2 (en) * 2005-09-22 2012-08-16 Megmilk Snow Brand Co., Ltd. Medicine, food and drink or feed containing sphingomyelin
WO2007059762A1 (de) * 2005-11-25 2007-05-31 Gisela Susilo Kombinationspräparate enthaltend physiologische zellmembran-bestandteile, einschliesslich phosphatidylserin, cholin und ein pyrimidinnukleos/tid
PL1800675T4 (pl) * 2005-12-23 2012-02-29 Nutricia Nv Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia
JP5140584B2 (ja) * 2006-06-27 2013-02-06 ヤマサ醤油株式会社 抗心理社会的ストレス剤
US7972633B2 (en) * 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
EP2217075A4 (en) * 2007-11-02 2012-01-25 Massachusetts Inst Technology URIDINE FOOD ADDITIONAL AGREEMENT PROCESS AND USE THEREOF
CA2727546A1 (en) * 2008-06-12 2009-12-17 Repligen Corporation Methods of treatment of bipolar disorder
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
JP6162125B2 (ja) 2011-09-30 2017-07-12 タフツ・ユニバーシティ 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法
WO2013066152A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2014027882A1 (en) 2012-08-13 2014-02-20 N.V. Nutricia Product and method for supporting uridine homeostasis
AU2013323188B2 (en) 2012-09-28 2018-04-19 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
AR095442A1 (es) 2013-03-13 2015-10-14 Univ Tufts Derivados de nucleósido de uridina, composiciones y métodos de uso
PT2968385T (pt) 2013-03-13 2018-10-09 Univ Tufts Derivados nucleósidos de uridina, composições e métodos de uso
WO2015115885A1 (en) * 2014-01-31 2015-08-06 N.V. Nutricia Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly
WO2016053085A1 (en) * 2014-09-30 2016-04-07 N.V. Nutricia Composition comprising a uridine source and butyrate producing fibres for preventing gastrointestinal disorders
WO2016072842A1 (en) * 2014-11-05 2016-05-12 N.V. Nutricia Method for preventing, reducing the risk of, or treating behavioral frontotemporal dementia
WO2017069613A1 (en) 2015-10-23 2017-04-27 N.V. Nutricia Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
US20190151273A1 (en) 2016-04-04 2019-05-23 N.V. Nutricia Method for reducing or preventing global developmental delay in children
KR20200116096A (ko) * 2018-02-01 2020-10-08 웰스태트 테러퓨틱스 코포레이션 우리딘의 전신 전달을 위한 조성물 및 장치
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
CN114990176A (zh) * 2022-05-26 2022-09-02 宁夏华吉生物有限公司 一种生产尿嘧啶核苷的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2508474A1 (de) * 1975-02-27 1976-09-02 Boehringer Mannheim Gmbh Infusions- und spuelfluessigkeiten zur behandlung von hirnoedemen
DE2629845A1 (de) * 1976-07-02 1978-01-05 Geb Graze Erika Graze Infusions- bzw. injektionsloesungen bzw. waessrige konzentrate zu deren bereitung zur therapeutischen restituion des zellulaeren energiestoffwechsels und der koerpereigenen regelfunktion
US4221784A (en) * 1979-04-05 1980-09-09 Massachusetts Institute Of Technology Process and composition for treating disorders by administering lecithin
IT1178044B (it) * 1984-10-09 1987-09-03 Polifarma Spa Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
US4609647A (en) * 1985-05-28 1986-09-02 Massachusetts Institute Of Technology Cytidyl diphosphocholine-drug composition and process
ES2007350A6 (es) * 1987-05-29 1989-06-16 Ganadera Union Ind Agro Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
DE3883374T2 (de) * 1987-10-28 1993-12-09 Pro Neuron Inc Acylatiertes uridin und cytidin und deren verwendungen.
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
RU2003332C1 (ru) * 1989-06-09 1993-11-30 Борис Витальевич Страдомский Средство дл лечени депрессий
JPH0722495B2 (ja) * 1990-01-30 1995-03-15 美穂 田中 クロレラ含有油脂食品
US5141943A (en) 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5700590A (en) * 1994-01-10 1997-12-23 Abbott Laboratories Nutritional formula with ribo-nucleotides
JPH07215879A (ja) * 1994-02-02 1995-08-15 Otsuka Pharmaceut Factory Inc 抗ストレス組成物
DE9412374U1 (de) * 1994-08-01 1994-09-22 Rauch-Petz, Gisela G., Dr., 80803 München Nahrungsergänzungsmittel
JPH0930976A (ja) * 1995-07-17 1997-02-04 Otsuka Pharmaceut Factory Inc 記憶低下改善剤
US5843024A (en) * 1996-05-17 1998-12-01 Breonics, Inc. Solution and process for resuscitation and preparation of ischemically damaged tissue
US5962459A (en) * 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
IT1290781B1 (it) * 1996-05-28 1998-12-10 Polifarma Spa Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
KR100879559B1 (ko) * 1999-02-23 2009-01-22 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 미토콘드리아 장애의 치료 또는 예방용 제약조성물
JP2001233776A (ja) * 2000-02-25 2001-08-28 Yamasa Shoyu Co Ltd 学習・記憶能低下改善剤およびその用途
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline

Also Published As

Publication number Publication date
ATE446097T1 (de) 2009-11-15
PT2329829E (pt) 2014-07-24
ES2477568T3 (es) 2014-07-17
US6989376B2 (en) 2006-01-24
DK2329829T3 (da) 2014-07-21
ES2476940T3 (es) 2014-07-15
DK2322187T3 (da) 2014-07-21
PT1140104E (pt) 2007-12-26
EP1870103A2 (en) 2007-12-26
EP1140104B1 (en) 2007-09-26
DK1870103T3 (da) 2010-01-11
DE69941586D1 (de) 2009-12-03
WO2000006174A1 (en) 2000-02-10
EP2322187A2 (en) 2011-05-18
CA2339008A1 (en) 2000-02-10
EP2329829B1 (en) 2014-04-16
ES2332669T3 (es) 2010-02-10
CY1110570T1 (el) 2015-04-29
EP1870103A3 (en) 2008-08-06
CA2339008C (en) 2009-12-15
DE69937198D1 (de) 2007-11-08
DK1140104T3 (da) 2008-01-21
EP2145627B1 (en) 2014-04-16
EP1140104A1 (en) 2001-10-10
US20020028787A1 (en) 2002-03-07
JP2003517437A (ja) 2003-05-27
PT1870103E (pt) 2010-02-23
EP2322187B1 (en) 2014-05-14
DE69937198T2 (de) 2008-07-03
EP2322187A3 (en) 2011-07-20
ATE374029T1 (de) 2007-10-15
ES2478044T3 (es) 2014-07-18
PT2322187E (pt) 2014-07-24
EP1140104A4 (en) 2004-12-22
EP1870103B1 (en) 2009-10-21
ES2294850T3 (es) 2008-04-01
EP2329829A2 (en) 2011-06-08
PT2145627E (pt) 2014-07-24
EP2145627A1 (en) 2010-01-20
EP2329829A3 (en) 2011-07-20

Similar Documents

Publication Publication Date Title
DK2145627T3 (da) Anvendelse af uridin i kombination med cholin til behandling af en humør-lidelse eller en følelsesmæssig lidelse.
DK1066036T3 (da) Midler med serotoninrelateret aktivitet til behandling af sövnapnö
DE59107331D1 (de) Flupirtin in Kombination mit Antiparkinsonika zur Bekämpfung von Muskelverspannungen
DK0450991T3 (da) Anvendelse af phospholipider til behandling af luftvejsobstruktionssygdomme
TR200101722T2 (tr) Serivastatin ve fibratların birleşimi.
MX9207008A (es) Medicamentos para el tratamiento de condiciones inflamatorias o para la analgesia.
ES2015512A4 (es) Proceso para la preparacion de polialcoholes de polieter con reducida saturacion.
DE69811158D1 (de) Verfahren zur Herstellung von 2,2-Bis(3-amino-4-hydroxyphenyl)-1,1,1,3,3,3-hexafluoropropan
DE69200684D1 (de) Vorrichtung zur thermischen Behandlung von laufenden Garnen.
DK1007055T3 (da) Anvendelse af amifostin
BR9915460A (pt) Método de tratamento de febre hemorrágica virótica
TR199900505T2 (da)
BR9914899A (pt) Uso de (r)-tofisopam opticamente puro para o tratamento e a prevenção de distúrbios de ansiedade e composição do mesmo
BR9711575A (pt) Emprego de 1-hidrÄxi-2-piridonas para o tratamento da dermatite seborr-ica
NO983311L (no) FremgangsmÕte for Õ forhindre sulfidst÷veksplosjoner i forbindelse med etterblÕsing
DE69734461D1 (de) Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom
ATE287718T1 (de) Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems
DK671087D0 (da) Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner som antikonvulsiva
MX9205459A (es) Compuesto de organosilicio para el tratamiento de fibras de poliester, metodo para el tratamiento de las fibras de poliester y las fibras asi producidas.
TR199801798T2 (xx) Otizm tedavisi.
NO900009L (no) Fremgangsmaate for fremstilling av aspiringranuler med regulert frigivningseffekt.
DK0880971T3 (da) Markofagstimulerende protein til behandling af sygdomme i centralnervesystemet
ES1027603Y (es) Estructura desmontable para el montaje de cajones.
ES1029541Y (es) Prenda para personas con trastornos mentales.
ES1020134Y (es) Mesa audiovisual para el juego de bingo.